The Role of Adjuvant Therapy in Duodenal Adenocarcinoma and Intestinal Subtype Ampullary Carcinoma After Curative Resection
Authors:
- 13 October 2023
- journal article
- research article
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 280 (6) , 986-992
Abstract
Objective: To define the role of adjuvant therapy in duodenal adenocarcinoma (DAC) and intestinal subtype ampullary carcinoma (iAC). Background: DAC and iAC share a similar histologic differentiation but the benefit of adjuvant therapy remains unclear. Methods: Patients undergoing curative intent surgical resection for DAC and iAC between 2010 and 2021 at 5 high-volume centers were included. Patient baseline, perioperative, and long-term oncological outcomes were evaluated. Statistical testing was performed with SPSS 25 (IBM). Results: A total of 136 patients with DAC and 171 with iAC were identified. Patients with DAC had more advanced tumors than those with iAC. Median overall survival (OS) in patients with DAC was 101 months versus 155 months for patients with iAC (P = 0.098). DAC had a higher rate of local (14.1% vs 1.2%, P < 0.001) and systemic recurrence (30.4% vs 3.5%, P < 0.001). Adjuvant therapy failed to improve OS in all patients with DAC and iAC. For DAC, patients with perineural invasion, but not other negative prognostic factors, had improved OS rates with adjuvant therapy (72 vs 44 m, P = 0.044). Patients with iAC with N+ (190 vs 57 m, P = 0.003), T3-T4 (177 vs 59 m, P = 0.050), and perineural invasion (150 vs 59 m, P = 0.019) had improved OS rates with adjuvant therapy. Conclusions: While adjuvant therapy fails to improve OS in all patients with DAC and iAC in the current study, it improved OS in patients with DAC with perineural invasion and in patients with iAC with T3-T4 tumors, positive lymph nodes, and perineural invasion.Keywords
This publication has 33 references indexed in Scilit:
- Impact of histopathological type on the prognosis of ampullary carcinoma: A systematic review and meta-analysisEuropean Journal of Surgical Oncology, 2022
- Metastatic small bowel adenocarcinoma: role of metastasectomy and systemic chemotherapyESMO Open, 2021
- Adjuvant therapy is associated with improved overall survival in patients with pancreatobiliary or mixed subtype ampullary cancer after pancreatoduodenectomy - A multicenter cohort studyPancreatology, 2020
- Role of Adjuvant Multimodality Therapy After Curative-Intent Resection of Ampullary CarcinomaJAMA Surgery, 2019
- Incidence and comparative outcomes of periampullary cancer: A population‐based analysis demonstrating improved outcomes and increased use of adjuvant therapy from 2004 to 2012Journal of Surgical Oncology, 2018
- Adjuvant chemotherapy versus chemoradiotherapy in the management of patients with surgically resected duodenal adenocarcinoma: A propensity score‐matched analysis of a nationwide clinical oncology databaseCancer, 2016
- Outcome after surgical resection for duodenal adenocarcinoma in the UKBritish Journal of Surgery, 2015
- 15-Year Experience with Surgical Treatment of Duodenal Carcinoma: a Comparison of Periampullary and Extra-Ampullary Duodenal CarcinomasJournal of Gastrointestinal Surgery, 2012
- Superior Prognostic Importance of Perineural Invasion vs. Lymph Node Involvement After Curative Resection of Duodenal AdenocarcinomaJournal of Gastrointestinal Surgery, 2012
- Postpancreatectomy hemorrhage (PPH)–An International Study Group of Pancreatic Surgery (ISGPS) definitionSurgery, 2007